PM
ORMP icon

Platinum Management’s Oramed Pharmaceuticals ORMP Stock Holding History

Platinum Management’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-26,573
Closed -$165K – 93
2013
Q3 		$165K Buy
+26,573
New +$189K 0.09% 54

Other funds holding ORMP

AWMDMG
Austin W. Marxe & David M. Greenhouse New York $733M AUM 21.72% 1-Year Est. Return
GIM
Greylin Investment Management Orange, Virginia $598M AUM 18.59% 1-Year Est. Return
TAM
Telluride Asset Management Wayzata, Minnesota $117M AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FNBT
FineMark National Bank & Trust Fort Myers, Florida $3.2B AUM 18.28% 1-Year Est. Return
U
UBS Zurich, Switzerland $136B AUM 16.36% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
HCM
Highlander Capital Management Short Hills, New Jersey $292M AUM 22.24% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
FNYS
First New York Securities New York $53.7M AUM 57.01% 1-Year Est. Return

Platinum Management's ORMP Position: Q4 2013 in Review

Platinum Management sold out of Oramed Pharmaceuticals (ORMP) in Q4 2013, closing a stake of 26,573 shares — an estimated $165K sold.

Platinum Management first reported a position in ORMP in Q3 2013 and held it in 1 quarter. The position peaked at $165K in Q3 2013. 15 funds tracked by Wall St. Rank hold ORMP as of Q4 2013.

  • Platinum Management reported no remaining Oramed Pharmaceuticals position as of Q4 2013 after selling out during the quarter.
  • Platinum Management sold 26,573 Oramed Pharmaceuticals shares in Q4 2013, an estimated $165K.
  • Platinum Management first reported a position in Oramed Pharmaceuticals in Q3 2013 and held it in 1 quarter.
  • Platinum Management's Oramed Pharmaceuticals position peaked at $165K in Q3 2013.
  • 15 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q4 2013.

Based on Platinum Management's 13F filing for Q4 2013, filed 14 Feb 2014.